Australia's Orthocell rises on FDA nod for US launch of nerve repair drug

Orthocell

04/04/2025 02:49

** Orthocell OCC.AX jumps 7% to A$1.53; set for biggest intraday percentage gain since March 17

** Biotech firm receives U.S. FDA clearance to begin commercially distributing its flagship Remplir nerve repair product in the U.S.

** Stock sees busiest session since late February - 3.2 million shares traded, 2.1x the 30-day avg

** OCC gains 13.3% YTD

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)

 ((JasmeenAraIslam.Shaikh@thomsonreuters.com;))